Osimertinib Safety Profile in NSCLC Treatment

Serious Adverse Effects

Interstitial lung disease (ILD)/pneumonitis is a significant adverse effect, occurring in 3.9-56% of patients, with fatal events reported, including 2 respiratory failure deaths and 1 pneumonitis death in clinical trials, according to the National Comprehensive Cancer Network 1, 2
Fatal events from pneumonitis have been reported, with 2 respiratory failure deaths and 1 pneumonitis death in clinical trials, as stated by the National Comprehensive Cancer Network 1, 2

The National Comprehensive Cancer Network recommends that patients with mean resting QTc >470 msec should not receive osimertinib, due to the risk of QTc prolongation 3
Concomitant QT-prolonging medications should be discontinued or substituted before initiating osimertinib, as advised by the National Comprehensive Cancer Network 3

Osimertinib demonstrates superior tolerability compared to platinum-based chemotherapy, with significantly fewer grade ≥3 adverse events (23% vs 47%), according to the National Comprehensive Cancer Network 1, 2, 4
Grade ≥3 adverse events occur in 23% of patients with osimertinib vs 47% with chemotherapy, as reported by the National Comprehensive Cancer Network 1, 2, 4

Baseline and periodic ECG monitoring for QTc prolongation is recommended, especially in patients with cardiac risk factors, by the National Comprehensive Cancer Network 3
Review and minimize concurrent QT-prolonging medications, as advised by the National Comprehensive Cancer Network 3

Osimertinib demonstrates a favorable safety profile with grade 3 or higher adverse events occurring in only 34% of patients as monotherapy, significantly better than older-generation EGFR TKIs (45%) and substantially superior to platinum-based chemotherapy (47% vs 23%) 5

Osimertinib increases QTc interval in a dose-dependent manner, with QTc prolongation occurring in 10% of patients in FLAURA (grade ≥3: 2.2%) 6

Osimertinib demonstrates superior tolerability compared to first/second-generation EGFR TKIs, with grade ≥3 adverse events: 34% with osimertinib vs 45% with erlotinib/gefitinib 5, 7, 8, 9
The National Comprehensive Cancer Network recommends osimertinib as a preferred treatment option due to its favorable safety profile, with CNS progression events: 6% with osimertinib vs 15% with erlotinib/gefitinib 5, 7, 8, 9